Cellectar Biosciences, Inc. — 2016 Form 10-K
Reporting period: Fiscal year ended December 31, 2016, compared with fiscal 2015. The filing provides annual results, not standalone fourth-quarter figures. Cellectar is a clinical-stage biopharmaceutical company developing phospholipid drug conjugates (PDCs) for cancer treatment and imaging; it reported no product revenue.
Financial performance and position
| Metric | 2016 | 2015 |
|---|---|---|
| Revenue | No product revenue reported | No product revenue reported |
| Research and development expense | $4.75 million | $5.16 million |
| General and administrative expense | $4.70 million | $3.40 million |
| Operating loss | $9.45 million | $8.76 million |
| Net loss | $6.18 million | $5.50 million |
| Net loss per share | $1.36 | $7.03 |
| Cash used in operations | $8.28 million | $8.21 million |
| Cash and cash equivalents at year-end | $11.44 million | $3.86 million |
Gross and operating margins are not meaningful because the company had no product revenue. The 2016 net loss included a $3.26 million non-cash gain from revaluation of derivative warrants. The per-share comparison is affected by the 1-for-10 reverse stock split in March 2016 and a substantial increase in weighted-average shares.
At December 31, 2016, working capital was approximately $10.5 million, total assets were $15.32 million, total liabilities were $1.78 million, and stockholders’ equity was $13.54 million. Notes payable totaled about $86,600, due within one year; the company also reported small capital-lease obligations. Cash increased largely because of equity offerings: financing activities provided $15.94 million in 2016. The company raised approximately $8.3 million net in its November offering and $7.2 million net in its April offering.
Material changes and business developments
- R&D expense declined 8% year over year, primarily due to lower personnel, laboratory, facility, and patent costs, partly offset by consulting costs related to planned clinical work.
- G&A expense increased 38%, reflecting higher personnel, accounting, consulting, investor-relations, public-company compliance, and legal costs. The 2015 period included $204,000 of restructuring costs; none were reported in 2016.
- CLR 131, the lead radiotherapeutic candidate, was in a Phase 1 study for relapsed or refractory multiple myeloma. In 2016, the Data Monitoring Committee supported dose escalation into Cohort 3. The company received a $2 million NCI SBIR grant to support a planned Phase 2 study.
- Paclitaxel PDC candidates CLR 1601-PTX, CLR 1602-PTX, and CLR 1603-PTX remained preclinical. A research collaboration with Pierre Fabre was intended to explore additional PDCs.
- CLR 124 imaging trials had concluded or completed enrollment, with the company evaluating the data. CLR 1502’s FDA combination-product classification required a new investigational application before a planned Phase 1 study.
Outlook, risks, and unusual items
Management estimated that year-end cash would fund budgeted operations into the first quarter of 2018. Continued operations beyond that point depend on raising additional capital, pursuing a strategic transaction, or other funding. The auditor’s report included a going-concern paragraph, citing recurring losses and an accumulated deficit of approximately $70.8 million; the statements contain no adjustments for the outcome of this uncertainty. Management expects continued operating losses and reported no assurance that needed financing will be available.
Financing brought substantial potential dilution. At year-end, the company reported 10.72 million outstanding warrants and 1.13 million shares issuable on conversion of preferred stock, as well as 471,433 stock options. In January 2017, remaining preferred shares converted into 1,133,339 common shares; through March 10, 2017, 1,336,218 Series C warrants were exercised for approximately $2.0 million. The cover page reported 12,837,882 common shares outstanding as of March 10, 2017.
Key risks include clinical or regulatory failure, dependence on additional financing and third-party manufacturing, competition, reimbursement and market-acceptance uncertainty, and intellectual-property risks. The company also noted that approximately $10.95 million of cash was uninsured at year-end. Nasdaq listing compliance issues from 2015–2016 were reported as resolved. Management concluded disclosure controls and internal control over financial reporting were effective at year-end 2016 and stated that the material weakness identified for 2015 had been remediated. The independent auditor did not attest to internal-control effectiveness.
Management’s expected Phase 2 start timing is described as the first half of 2017 in the business discussion and first quarter of 2017 in MD&A; the filing does not provide a single consistent target date. The NCI grant was awarded in July 2016.
Investor verification priorities
- Confirm current cash, operating burn, financing needs, and whether the stated runway remains achievable.
- Review the latest CLR 131 clinical data, trial enrollment, safety findings, and actual Phase 2 timing and funding.
- Assess dilution from outstanding warrants, preferred-stock conversions, options, and subsequent warrant exercises.
- Verify regulatory plans and required filings for CLR 1502, and the company’s evaluation and next steps for CLR 124.
- Review the going-concern disclosure, the auditor’s explanatory paragraph, and the company’s internal-control remediation disclosures.